ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
Go back to ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results| Solar 18 Corporation (NASDAQ: SLRN) | Delayed: 2.27 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.27 | 52 Week High | $0.01 | |||
| Open | $2.27 | 52 Week Low | $0.00 | |||
| Day High | $2.27 | P/E | N/A | |||
| Day Low | $2.27 | EPS | $0.00 | |||
| Volume | 20 | |||||
| Solar 18 Corporation (NASDAQ: SLRN) | Delayed: 2.27 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.27 | 52 Week High | $0.01 | |||
| Open | $2.27 | 52 Week Low | $0.00 | |||
| Day High | $2.27 | P/E | N/A | |||
| Day Low | $2.27 | EPS | $0.00 | |||
| Volume | 20 | |||||
